49.51
+0.88
(1.81%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
| Range | 48.35 - 49.62 |
| 52 week | 36.73 - 49.86 |
| Open | 48.71 |
| Vol / Avg. | 976,865.00/760,274.00 |
| Mkt cap | 3,203.97M |
| P/E | 28.62 |
| Div/yield | - |
| EPS | 1.73 |
| Shares | 64.71M |
| Beta | 0.54 |
| Inst. own | 113% |
Events
Jul 17, 2013
Q2 2013 Cubist Pharmaceuticals, Inc. Earnings Release
Jun 12, 2013
Cubist Pharmaceuticals, Inc. Annual Shareholder Meeting
- 8:30am GMT-4 -
May 15, 2013
Cubist Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
Apr 18, 2013
Q1 2013 Cubist Pharmaceuticals, Inc. Earnings Conference Call
Apr 18, 2013
Q1 2013 Cubist Pharmaceuticals, Inc. Earnings Release
Mar 4, 2013
Cubist Pharmaceuticals, Inc. at Cowen Health Care Conference
Feb 26, 2013
Cubist Pharmaceuticals, Inc. at RBC Capital Markets' Healthcare Conference
| More events from DailyFinance » |
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 2.65% | 16.63% |
| Operating margin | 4.26% | 25.60% |
| EBITD margin | - | 33.37% |
| Return on average assets | 1.27% | 8.08% |
| Return on average equity | 2.44% | 17.21% |
| Employees | 762 | - |
| Carbon Disclosure Rating | - | - |
Address
65 Hayden Avenue
LEXINGTON, MA 02421-7994
United States - Map
+1-781-8608660 (Phone)
+1-302-6555049 (Fax)
LEXINGTON, MA 02421-7994
United States - Map
+1-781-8608660 (Phone)
+1-302-6555049 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). As of December 31, 2011, the Company had three drug candidates in late-stage clinical trials. On December 12, 2011, the Company acquired Adolor Corporation (Adolor) and rights to ENTEREG.
Officers and directors
| Robert J. Perez | President, Chief Operating Officer | |
| Michael W. Bonney | Chief Executive Officer, Director | |
| Michael Tomsicek | Chief Financial Officer, Senior Vice President, Treasurer | |
| Steven C. Gilman Ph.D. | Executive Vice President - Research and Development, Chief Scientific Officer | |
| Patrick Vink M.D. | Senior Vice President, General Manager - International Business | |
| Charles Laranjeira | Senior Vice President - Technical Operations | |
| Thomas Rollins | Senior Vice President - Program and Portfolio Management | |
| Gregory Stea | Senior Vice President - Commercial Operations | |
| Kenneth M. Bate | Non-Executive Independent Chairman of the Board | |
| Mark H. Corrigan M.D. | Independent Director |